Pyrazole derivatives

Details Pyrazole derivatives Pyrazole derivatives

2007-06-12

2007-06-12

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S364100, C548S366100

Reexamination Certificate

active

10669812

ABSTRACT:
This invention relates to pyrazole derivatives of formula (I)or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1to R4are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

REFERENCES:
patent: 3303200 (1967-02-01), Wolf et al.
patent: 5189040 (1993-02-01), Ohsumi et al.
patent: 0 208 874 (1986-05-01), None
patent: 0 459 333 (1991-12-01), None
patent: 0 649 056 (1994-10-01), None
patent: 0 658 806 (1994-10-01), None
patent: 1 140 898 (1969-01-01), None
patent: 0222374.1 (2002-09-01), None
patent: 0223356.7 (2002-10-01), None
patent: 62149617 (1987-03-01), None
patent: 01 125379 (1989-05-01), None
patent: 03 141276 (1989-06-01), None
patent: WO 89/10925 (1989-11-01), None
patent: WO 91/11172 (1991-08-01), None
patent: WO 94/02518 (1994-02-01), None
patent: WO 98/55148 (1998-12-01), None
patent: WO 02/04424 (2002-01-01), None
patent: WO 02/30907 (2002-04-01), None
U.S. Appl. No. 60/433,402, filed Dec. 13, 2002, Pfizer, Inc.
Berge, Stephen M., et al., “Pharmaceutical Salts,”J.Pharm.Sci.,1977, pp. 1-19, vol. 66 No. 1.
Bighely, Lyle D., et al., “Salt Forms of Drugs and Absorption,”Encyclopedia of Pharmaceutical Technology,1996, pp. 453-497, vol. 13, Marcel Dekker Inc., New York, USA.
Bundgarrd, Hans, ed., “Design of prodrugs: Bioreversible derivative for various functional groups and chemical entitites,” 1985,Design of Prodrugs,Chapter 1, pp. 1-92, Elsevier Science Publishers Biomedical Division.
Coppola, Gary M., et al., “Pyrimindones. 2. Synthesis and Reactions of 2-Chloropyrimidines,”J.Het.Chem,1980, pp. 1479-1482, vol. 17(7).
Ferres, Harry, “Pro-Drugs of β-Lactam Antibiotics,”Drugs of Today,pp. 499-538, 1983, vol. 19, No. 9.
Genin, Michael J., et al., “Novel 1,5-Diphenylpryazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity versus the Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives,”J.Med.Chem,2000, pp. 1034-1040, vol. 43.
Greene, Theodora W., et al., “Protective Groups in Organic Synthesis,” 1991, 2ndEdition, John Wiley & Sons, Inc., New York, USA.
Katritsky, Alan R., FRS, et al., “Comprehensive Heterocyclic Chemistry, The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds,” 1984, Pergamon Press, New York, USA.
Boeckman, Robert K., Jr., “A Novel Route to 2,3-Pyrazol-1(5H)-ones via Palladium-Catalyzed Carbonylation of 1,2-Diaza-1,3-butadienes,”Organic Letters,2001, 3651-3653, vol. 3, No. 23.
Hendess, Raymond W., “1-Phenyl-2-acyl-3-amino-2-pyrazolin-5-ones from 1-Phenyl-3-azidocarbonyl-2-pyrazolin-5-ones,”Journal of Organic Chemistry,1972, 2400-2401, vol. 37, No. 15.

Affiliated with

Also associated with

Rating

Pyrazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3841047